Use your browser's BACK button to return to your page of origin.
Genital human papillomavirus infection.
Clinical Infectious Diseases 2006; 43:624-629.
Dunne E, Markowitz L.
Abstract
Over the past few decades, epidemiology and natural history studies have led
to improved understanding of human papillomavirus (HPV) infection and to
promising prevention strategies. HPV infection is the cause of anogenital
warts and cervical cancer, as well as a proportion of other anogenital and
head and neck cancers. Data from clinical trials have resulted in recommendations
that support the use of an HPV test in the context of cervical cancer screening
and management. Prophylactic HPV vaccine trials have demonstrated high efficacy,
and an HPV vaccine that prevents cervical cancer precursors, cervical cancer,
and anogenital warts caused by HPV types 6, 11, 16, and 18 was licensed for
use in girls and women aged 9-26 years by the US Food and Drug Administration
(FDA) in June 2006. In this article, we review genital HPV for the clinician,
with a primary focus on the prevalence of HPV infection in the United States.